



Bharat Parenterals Limited

Registered Office & Works:

Vill. Haripura, Ta. Savli, Dist. Vadodara - 391520 (Guj.) India.

Tele : (02667) - 251680, 251670, 99099 28332.

E-mail: info@bplindia.in, Web.: www.bplindia.in

CIN NO: L24231GJ1992PLC018237

(WHO-GMP CERTIFIED ★ STAR EXPORT HOUSE)

Date: 30th October, 2021

To,
BSE Limited,
P.J. Towers,
Dalal Street,
Mumbai - 400001

Ref.: Company Code: 541096

Dear Sir / Madam,

Sub: Outcome of the Board Meeting and Submission of Unaudited Financial Results for the Quarter and Half Year ended 30th September, 2021.

In compliance of Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company in its meeting held on 30th October, 2021, has considered and approved the Unaudited Financial Results for the Quarter and half year ended 30th September, 2021 and taken on record Limited Review Report issued by the Statutory Auditors of the Company.

In this respect, we hereby enclose following:

1. Unaudited Financial Results for the Quarter and Half year ended 30th September, 2021.
2. Limited Review Report on the said Financial Results.

The meeting of Board of Directors commenced at 02.30 p.m. and concluded at 03:00 p.m.

Request you to please take the same on record.

Thanking You,

FOR BHARAT PARENTERALS LIMITED

**Lubhanshi Jhalani
Company Secretary**



Corporate Office:

BHARAT PARENTERALS LIMITED

Regd. Office : Vill Haripura, TA Savli, District: Vadodara - 391 520

Corporate Office : Shree Avenue, 1st Floor, Above Bank of Baroda, Near Amit Nagar Circle, VIP Road, Karelibaug, Vadodara - 390 018

CIN:L24231GJ1992PLC018237

Website: www.bplindia.in

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEMBER, 2021

(Amount RS. in Lakhs)

Sr. No.	Particular	Quarter Ended			Half Year Ended		Year Ended
		30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	31.03.2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	A. Revenue from operations	6,040	6,084	5,957	12,124	11,350	20,367
	B. Other Income	252	176	204	428	454	867
	Total income	6,292	6,260	6,161	12,552	11,804	21,234
2	Expenses						
	A. Cost of materials consumed	3,735	3,832	4,196	7,567	7,610	12,713
	B. Purchase of Stock-in-Trade	43	86	57	129	101	502
	C. Changes in inventories of finished goods, work-in-progress and stock-in-trade	114	(97)	(400)	17	(271)	188
	D. Employee benefit expense	391	378	340	769	686	1,439
	E. Finance costs	15	29	13	44	20	76
	F. Depreciation and amortisation expense	172	174	142	346	270	603
	G. Other Expenses	745	815	911	1,560	1,586	3,011
	Total expenses	5,215	5,217	5,259	10,432	10,002	18,532
3	Total profit before tax	1,077	1,043	903	2,120	1,803	2,702
4	Tax expense						
	Current tax	288	280	250	568	489	732
	Deferred tax	(13)	(13)	8	(26)	30	(28)
	Short / (Excess) provision of tax in respect of earlier years	-	-	-	-	-	(23)
	Total tax expenses	275	267	257	542	519	681
5	Net Profit / (loss) for period	802	776	645	1,578	1,284	2,021
6	Other comprehensive Income						
	Items that will not be reclassified to profit or loss						
	Remeasurement of defined benefit obligation	6	5	1	11	3	21
	Income tax relating to Remeasurement of Defined benefit plans	(2)	(1)	(0)	(3)	(1)	(5)
	Other comprehensive Income for the year, net of taxes	4	4	1	8	2	16
7	Total Comprehensive Income for the period	806	780	646	1,586	1,285	2,037
8	Equity						
	a) Equity Share Capital (Face Value of Rs. 10/- each)						573
	b) Other Equity						13,821
9	Earnings per share						
	Basic (Rs.)	13.99	13.54	11.26	27.53	22.40	35.27
	Diluted (Rs.)	13.99	13.54	11.26	27.53	22.40	35.27

See accompanying notes to the Financial Results

- The Above Unaudited Standalone Financial Results have been duly reviewed by statutory auditors, recommended by the audit committee and approved by the board of Directors of the company at its meeting held on 30th October, 2021.
- The Company has only one segment of activity, namely "Pharmaceuticals."
- The outbreak of Corona virus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activity. The Company has evaluated impact of this pandemic on its business operations and based on its review and current indicators of future economic conditions, there is no significant impact on its financial results.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

By the order of Board of Director
For Bharat Parenterals Limited

(Signature)

Bharat R. Desai
Managing Director
Place : Vadodara

Date : 30th October, 2021



BHARAT PARENTERALS LIMITED

Regd. Office : Vill Haripura, TA Savli, District: Vadodara - 391 520
Corporate Office : Shree Avenue, 1st Floor, Above Bank of Baroda, Near Amit Nagar Circle, VIP Road,
Karelibaug, Vadodara - 390 018
CIN:L24231GJ1992PLC018237
Website: www.bplindia.in

STATEMENT OF UNAUDITED STANDALONE ASSETS AND LIABILITIES AS AT 30th SEPTEMBER, 2021

Amount Rs. in Lakhs

Sr. No.	Particulars	As at 30th September, 2021	As at 31st March, 2021
	ASSETS		
(1)	Non current Assets		
	(a) Property, Plant and Equipment	4,245	4,336
	(b) Investment Properties	114	119
	(c) <u>Financial Assets</u>		
	(i) Investments	482	3
	(ii) Other Financial assets	266	353
	(d) Other Non Current Assets	141	110
(2)	Current assets		
	(a) Inventories	2,728	2,243
	(b) <u>Financial Assets</u>		
	(i) Investments	3,019	4,179
	(ii) Trade receivables	7,640	6,783
	(iii) Cash and cash equivalents	66	140
	(iv) Bank Balances other than Cash and cash equivalents	162	75
	(v) Loans	14	8
	(vi) Other financial assets	2,340	268
	(c) Other current assets	934	974
	(d) Current Tax Asset (Net)	-	32
	Total Assets	22,151	19,624
	EQUITY AND LIABILITIES		
(1)	Equity		
	(a) Equity Share capital	573	573
	(b) Other Equity	15,463	13,821
	Total equity attributable to equity holders of the Company	16,036	14,394
(2)	LIABILITIES		
	Non-Current liabilities		
	(a) <u>Financial Liabilities</u>		
	(i) Borrowings	741	859
	(b) Provisions	71	64
	(c) Deferred tax liabilities (Net)	174	197
(3)	Current liabilities		
	(a) <u>Financial Liabilities</u>		
	(i) Borrowings	411	365
	(ii) Trade payables		
	a) total outstanding dues of Micro Enterprises and Small Enterprises	450	71
	b) total outstanding dues of creditors other than Micro Enterprises and Small Enterprises	3,026	2,546
	(iii) Other financial liabilities	690	709
	(b) Other current liabilities	296	334
	(c) Provisions	99	84
	(d) Current Tax Liabilities (Net)	156	-
	Total Liabilities	6,115	5,229
	Total Equity and Liabilities	22,151	19,624

By the order of Board of Director
For Bharat Parenterals Limited



Bharat R. Desai
Managing Director
Place : Vadodara

Date : 30th October, 2021



BHARAT PARENTERALS LIMITED

Regd. Office : Vill Haripura, TA Savli, District: Vadodara - 391 520

Corporate Office : Shree Avenue, 1st Floor, Above Bank of Baroda, Near Amit Nagar Circle, VIP Road,

Karelbaug, Vadodara - 390 018

CIN:L24231GJ1992PLC018237

Website: www.bplindia.in

STANDALONE STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED 30th SEPTEMBER, 2021

		Amount Rs. in Lakhs	
Particulars		Half year ended 30th September, 2021	Half year ended 30th September, 2020
A	Cash flow from operating activities		
	Profit before income tax	2,120	1,803
	Adjustments for :		
	Depreciation and amortisation expense	346	270
	(Gain)/ Loss on Sales of Property, Plant and Equipments (Net)	(3)	-
	Fair valuation of Investments through FVTPL	(80)	(1)
	(Gain)/ Loss on Sales of Investment (Net)	(11)	(8)
	Dividend Income	-	(0)
	Rent Income	-	(1)
	Finance Cost	44	20
	Interest Income	(66)	(18)
	Operating profit before working capital changes	2,350	2,065
	Movements in working capital:		
	Current Assets		
	(Increase) / Decrease in Trade Receivables	(857)	(267)
	(Increase) / Decrease in Inventories	(485)	(508)
	(Increase) / Decrease in Other Financial Assets	(1,924)	40
	(Increase) / Decrease in Loans	(7)	(1)
	(Increase) / Decrease in Other Current Assets	40	229
	(Increase) / Decrease in Other Non Current Assets	(31)	(175)
	Current Liabilities		
	Increase / (Decrease) in Trade Payables	860	(81)
	Increase / (Decrease) in Provisions	22	32
	Increase / (Decrease) in Other Current Liabilities	(38)	15
	Increase / (Decrease) in Other Financial Liabilities	(19)	(748)
	Cash generated from operations :	(88)	602
	Direct taxes paid (net)	313	324
	Net cash from operating activities (A)	(401)	278
	Cash flows from investing activities		
B	Purchase of Property, plant and equipments (Including Capital work in progress and capital advances)	(249)	(220)
	Proceeds of sale of Property, plant and equipments	4	-
	(Increase) / Decrease in Other Bank Balances	(87)	(69)
	Purchase/(Sale) of investments	771	(275)
	Dividend Received	-	0
	Rent Received	-	1
	Interest Received	5	7
	Net cash (used) in Investing activities (B)	443	(556)
	Cash flow from financing activities :		
C	Finance Cost	(44)	(20)
	Proceeds/ (Repayment) of Borrowings	(72)	(49)
	Net cash (used) in financing activities (C)	(116)	(69)
	NET INCREASE IN CASH AND CASH EQUIVALENTS [(A) + (B) + (C)]	(75)	(348)
	CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	140	969
	CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR	66	621

By the order of Board of Director
For Bharat Parenterals Limited

Bharat R. Desai
Managing Director

Place : Vadodara

Date : 30th October, 2021



BHARAT PARENTERALS LIMITED

Regd. Office : Vill Haripura, TA Savli, District: Vadodara - 391 520

Corporate Office : Shree Avenue, 1st Floor, Above Bank of Baroda, Near Amit Nagar Circle, VIP Road, Karelibaug, Vadodara - 390 018

CIN:L24231GJ1992PLC018237

Website: www.bplindia.in

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEMBER, 2021

Sr. No.	Particular	Amount Rs. In Lakhs					
		Quarter Ended			Half Year Ended		Year Ended
		30.09.2021 (Unaudited)	30.06.2021 (Unaudited)	30.09.2020 (Unaudited)	30.09.2021 (Unaudited)	30.09.2020 (Unaudited)	31.03.2021 (Audited)
1	A. Revenue from operations B. Other Income	6,040 252	6,084 176	5,957 204	12,124 428	11,448 454	20,464 867
	Total Income	6,292	6,260	6,161	12,552	11,902	21,332
2	Expenses						
	A. Cost of materials consumed	3,735	3,832	4,196	7,567	7,610	12,713
	B. Purchase of Stock-in-Trade	43	86	57	129	132	533
	C. Changes in inventories of finished goods, work-in-progress and stock-in-trade	114	(97)	(400)	17	(279)	180
	D. Employee benefit expense	394	378	340	772	722	1,475
	E. Finance costs	15	29	13	44	20	77
	F. Depreciation and amortisation expense	172	174	142	346	270	603
	G. Other Expenses	754	822	911	1,576	1,599	3,038
	Total expenses	5,228	5,223	5,259	10,451	10,074	18,619
3	Total profit before tax	1,064	1,037	903	2,101	1,828	2,712
4	Tax expense						
	Current tax	288	280	250	568	489	732
	Deferred tax	(13)	(13)	8	(26)	30	(28)
	Short / (Excess) provision of tax in respect of earlier years	-	-	-	-	-	(23)
	Total tax expenses	275	267	257	542	519	681
5	Net Profit / (loss) for period	789	770	645	1,559	1,309	2,032
6	Other comprehensive Income						
	Items that will not be reclassified to profit or loss						
	Remeasurement of defined benefit obligation	6	5	1	11	3	21
	Income tax relating to Remeasurement of Defined benefit plans	(2)	(1)	(0)	(3)	(1)	(5)
	Other comprehensive Income for the year, net of taxes	4	4	1	8	2	16
7	Total Comprehensive Income for the period	793	774	646	1,567	1,311	2,047
	Net Profit attributable to:						
	Owners of the company	795	773	645	1,568	1,309	2,039
	Non Controlling Interest	(6)	(3)	-	(9)	-	(7)
	Other Comprehensive Income attributable to:						
	Owners of the company	4	4	1	8	2	16
	Non Controlling Interest	-	-	-	-	-	-
	Total Comprehensive Income for the period						
	Owners of the company	799	777	646	1,576	1,311	2,055
	Non Controlling Interest	(6)	(3)	-	(9)	-	(7)
8	Equity						
	a) Equity Share Capital (Face Value of Rs. 10/- each)						573
	b) Other Equity						13,814
9	Earnings per share						
	Basic (Rs.)	13.88	13.49	11.26	27.37	22.85	35.59
	Diluted (Rs.)	13.88	13.49	11.26	27.37	22.85	35.59

See accompanying notes to the Financial Results

- The Above Unaudited Consolidated Financial Results have been duly reviewed by statutory auditors, recommended by the audit committee and approved by the board of Directors of the company at its meeting held on 30th October, 2021.
- The Company has only one segment of activity, namely "Pharmaceuticals."
- The outbreak of Corona virus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activity. The Company has evaluated impact of this pandemic on its business operations and based on its review and current indicators of future economic conditions, there is no significant impact on its financial results.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

By the order of Board of Director
For Bharat Parenterals Limited


Bharat R. Desai
Managing Director

Place : Vadodara
Date : 30th October, 2021



BHARAT PARENTERALS LIMITED


Regd. Office : Vill Haripura, TA Savli, District: Vadodara - 391 520
Corporate Office : Shree Avenue, 1st Floor, Above Bank of Baroda, Near Amit Nagar Circle, VIP Road,
Karelibaug, Vadodara - 390 018
CIN:L24231GJ1992PLC018237
Website: www.bplindia.in

STATEMENT OF UNAUDITED CONSOLIDATED ASSETS AND LIABILITIES AS AT 30th SEPTEMBER, 2021

Amount Rs. In Lakhs

Sr. No.	Particulars	As at 30th September, 2021	As at 31st March, 2021
	ASSETS		
(1)	Non current Assets		
	(a) Property, Plant and Equipment	4,245	4,336
	(b) Capital work-in-progress	985	44
	(c) Investment Properties	114	119
	(d) <u>Financial Assets</u>		
	(i) Other Financial assets	266	353
	(e) Other Non Current Assets	190	210
(2)	Current assets		
	(a) Inventories	2,728	2,243
	(b) <u>Financial Assets</u>		
	(i) Investments	3,019	4,279
	(ii) Trade receivables	7,640	6,783
	(iii) Cash and cash equivalents	67	168
	(iv) Bank Balances other than Cash and cash equivalents	162	75
	(v) Loans	14	8
	(vi) Other financial assets	2,340	268
	(c) Other current assets	914	946
	(d) Current Tax Asset (Net)	-	32
	Total Assets	22,684	19,865
	EQUITY AND LIABILITIES		
(1)	Equity		
	(a) Equity Share capital	573	573
	(b) Other Equity	15,446	13,814
	(c) Non Controlling Interest	447	(5)
	Total equity attributable to equity holders of the Company	16,466	14,382
(2)	LIABILITIES		
	Non-Current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	741	859
	(b) Provisions	71	64
	(c) Deferred tax liabilities (Net)	174	197
(3)	Current liabilities		
	(a) <u>Financial Liabilities</u>		
	(i) Borrowings	411	365
	(ii) Trade payables		
	a) total outstanding dues of Micro Enterprises and Small Enterprises	450	71
	b) total outstanding dues of creditors other than Micro Enterprises and Small Enterprises	3,058	2,546
	(iii) Other financial liabilities	760	959
	(b) Other current liabilities	299	337
	(c) Provisions	99	84
	(d) Current Tax Liabilities (Net)	156	-
	Total Liabilities	6,219	5,483
	Total Equity and Liabilities	22,684	19,865

By the order of Board of Director
For Bharat Parenterals Limited



Bharat R. Desai
Managing Director
Place : Vadodara
Date : 30th October, 2021



BHARAT PARENTERALS LIMITED


Corporate Office : Shree Avenue, 1st Floor, Above Bank of Baroda, Near Amit Nagar Circle, VIP Road,
Karelibaug, Vadodara - 390 018
CIN:L24231GJ1992PLC018237
Website: www.bplindia.in

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED 30th SEPTEMBER, 2021

Amount Rs. In Lakhs

Particulars		Half year ended 30th September, 2021	Half year ended 30th September, 2020
A	Cash flow from operating activities		
	Profit before income tax	2,101	1,828
	Adjustments for :		
	Share of (Profit)/Loss to minority	9	-
	Depreciation and amortisation expense	346	270
	Adjustment due to loss on disposal of subsidiary	-	470
	(Gain)/ Loss on Sales of Property, Plant and Equipments (Net)	(3)	-
	Fair valuation of Investments through FVTPL	(80)	(1)
	(Gain)/ Loss on Sales of Investment (Net)	(11)	(8)
	Dividend Income	-	(0)
	Rent Income	-	(1)
	Finance Cost	44	20
	Interest Income	(66)	(18)
	Operating profit before working capital changes	2,341	2,560
	Movements in working capital:		
	Current Assets		
	(Increase) / Decrease in Trade Receivables	(857)	(502)
	(Increase) / Decrease in Inventories	(485)	(396)
	(Increase) / Decrease in Other Financial Assets	(1,924)	45
	(Increase) / Decrease in Loans	(7)	-
	(Increase) / Decrease in Other Current Assets	32	(151)
	(Increase) / Decrease in Other Non Current Assets	20	(175)
	Current Liabilities		
	Increase / (Decrease) in Trade Payables	891	(74)
	Increase / (Decrease) in Provisions	22	32
	Increase / (Decrease) in Other Current Liabilities	(38)	(7)
	Increase / (Decrease) in Other Financial Liabilities	(199)	(703)
	Cash generated from operations :	(204)	630
	Direct taxes paid (net)	313	324
	Net cash from operating activities (A)	(518)	306
	Cash flows from investing activities		
B	Purchase of Property, plant and equipments (Including Capital work in progress and capital advances)	(1,190)	(220)
	Proceeds of sale of Property, plant and equipments	4	-
	(Increase) / Decrease in Other Bank Balances	(87)	(69)
	Purchase/(Sale) of investments	1,351	(300)
	Dividend Received	-	0
	Rent Received	-	1
	Interest Received	5	7
	Net cash (used) in Investing activities (B)	81	(581)
	Cash flow from financing activities :		
C	Finance Cost	(44)	(20)
	Proceeds/(Repayment) of Borrowings	(72)	(94)
	Increase / (Decrease) in Non controlling Interest	451	-
	Net cash (used) in financing activities (C)	335	(114)
	NET INCREASE IN CASH AND CASH EQUIVALENTS [(A) + (B) + (C)]	(101)	(389)
	CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	168	1,010
	CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR	67	621

By the order of Board of Director
For Bharat Parenterals Limited



Bharat R. Desai
Managing Director
Place : Vadodara
Date : 30th October, 2021



Independent Auditor's Review Report on Unaudited Standalone Quarterly and year to date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Bharat Parenterals Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial results of Bharat Parenterals Limited ("the Company") for the quarter ended 30th September, 2021 and year to date from 01st April, 2021 to 30th September, 2021 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited standalone financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

For CNK & Associates LLP

Chartered Accountants

Firm Registration No. 101961W/W-100036

Alok Shah



Alok Shah

Partner

Membership No. 042005

Place : Vadodara

Date : 30th October, 2021

UDIN : 21042005AAAAQU3865

Independent Auditor's Review Report on Unaudited Consolidated Quarterly and year to date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Bharat Parenterals Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of **Bharat Parenterals Limited** ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 30th September, 2021 and year to date from 01st April, 2021 to 30th September, 2021 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable



VADODARA : The Nirat, 3rd Floor, 18, Windward Business Park, Behind Emerald One Complex, In The Lane of Dr. Prashant Buch, Jetalpur Road, Vadodara - 390 007
● Tel: +91 265 234 3483, +91 265 235 4359 ● Email : vadodara@cnkindia.com

MUMBAI - HO : 3rd Floor, Mistry Bhavan, Dinshaw Vachha Road, Churchgate, Mumbai 400 020, India. ● Tel: +91 22 6623 0600

Website: www.cnkindia.com


MUMBAI | BENGALURU | CHENNAI | AHMEDABAD | GANDHINAGAR | DELHI | DUBAI | SHARJAH

4. The statement includes results of the following entity:
- i. Innoxel Lifesciences Private Limited (Subsidiary)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the financial result of a subsidiary included in the unaudited consolidated financial results, whose unaudited financial results reflects total assets of Rs. 1,050.45 Lakhs as at 30th September, 2021, total revenue of Rs. Nil, total net loss after tax of Rs. Rs. 12.66 Lakhs and Rs. 18.72 lakhs, total comprehensive loss of Rs. 12.66 lakhs and Rs. 18.72 Lakhs for the quarter ended 30th September, 2021 and the period ended on that day respectively. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of a subsidiary, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the unaudited consolidated quarterly financial results is not modified with respect of the above matter.

For CNK & Associates LLP

Chartered Accountants

Firm Registration No. 101961W/W-100036



Alok Shah

Partner

Membership No. 042005

Place : Vadodara

Date : 30th October, 2021

UDIN : 21042005AAAAQV6190